TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07571161: A Study of Donanemab Versus Placebo in Chinese Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease

Sponsor: Eli Lilly and Company · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 140 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$3,360,856

Rescue Site Savings

+$2,203,840

Unlock Full NCT07571161 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07571161 Rescue Dossier →